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Abstract Uteroglobin (UG) is an anti-inﬂammatory protein se-
creted by the airway epithelia of all mammals. UG-knockout
(UG-KO) mice sporadically develop focal pulmonary ﬁbrosis
(PF), a group of complex interstitial disorders of the lung that
has high mortality and morbidity; however, the molecular mech-
anism(s) remains unclear. We report here that UG-KO mice are
extraordinarily sensitive to bleomycin, an anti-cancer agent
known to induce PF and readily develop PF when treated with
an extremely low dose of bleomycin that has virtually no eﬀect
on the wild type littermates. We further demonstrate that UG
prevents PF suppressing bleomycin-induced production of pro-
inﬂammatory T-helper 2 cytokines and TGF-b, which are also
pro-ﬁbrotic. Our results deﬁne a critical role of UG in preventing
the development of PF and provide the proof of principle that re-
combinant UG may have therapeutic potential.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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1. Introduction
Uteroglobin (UG) or Clara cell 10 kDa (CC10) protein, the
founding member of the newly recognized Secretoglobin super-
family [1], is a steroid-inducible, multifunctional protein se-
creted by the airway epithelia of all mammals, including
humans (for review see Ref. [2]). Non-steroidal hormones,
such as prolactin, has been reported to augment the eﬀects
of steroid hormones [3]. In numerous experiments, it has been
demonstrated that this protein has potent anti-inﬂammatory
and anti-chemotactic properties. We previously noted that
UG-knockout (UG-KO) mice [4], generated by targeted dis-
ruption of the UG gene in embryonic stem (ES) cells, with
age sporadically develop focal pulmonary ﬁbrosis (PF). PF is
a complex disease with high mortality and morbidity [5,6].
However, the molecular mechanism(s) of PF in UG-KO mice
is not clearly understood. As stated above, UG is secreted by
the mucosal epithelial cells that line the airways of all mam-
mals and these cells have emerged as the key site of initial in-
jury that precedes the development of PF [7]. Thus, UG may
play a protective role against the development of PF.
Bleomycin, an anti-cancer drug, is limited in its clinical use
in humans because it causes widespread alveolar epithelial
cell injury and mediates the development of PF [7]. The later
property of this drug has been widely used to generate animal
models of PF [6]. Due to the lack of an eﬀective treatment,
PF is a disease with high mortality [5,6]. Understanding the
molecular mechanism(s) of pathogenesis of this disease may
facilitate the development of rational therapeutic approaches.
The generation of UG-KO mice, which sporadically develop
focal PF, provided an opportunity to understand the molec-
ular mechanism(s) by which UG may play a protective role
against PF.
The pathologic features of PF include progressive alveolar
inﬂammation, deposition of extracellular matrix proteins such
as collagen and proliferation of ﬁbroblasts. Although themolec-
ular mechanisms of this group of diseases remain unclear, it ap-
pears that a breakdown of homeostatic mechanisms to prevent
pulmonary inﬂammation plays critical pathogenic roles. How-
ever, it has been reported that injury to the mucosal epithelial
layer that lines the mammalian airways is one of the primary
events that leads to PF [7]. We previously reported that UG-
KO mice manifest exaggerated pulmonary inﬂammation when
challenged with allergens such as ovalbumin (OVA; Ref.
[8,9]). Most importantly, recombinant UG treatment abrogates
allergen-induced inﬂammation in the lungs of these mice. Since
airway inﬂammation precedes PF and since UG is a potent anti-
inﬂammatory protein present in the airways, we sought to deter-
mine whether UG may have protective roles against PF.
Here we report that mice lacking UG manifest extreme sen-
sitivity to bleomycin and are highly predisposed to developing
PF even when these mice are treated with the lowest dose of
this drug that does not appear to aﬀect the WT littermates.
The results of our study suggest that UG plays a pivotal role
in maintaining homeostasis in the airways by preventing
TH2–mediated inﬂammation and the development of PF.
2. Materials and methods
2.1. Animals
UG-knockout (UG-KO) mice were generated as described previ-
ously [4]. Animals were housed and maintained under germ-free condi-
tion, and all experiments were performed according to a protocol
approved by the NICHD Animal Care and Use Committee.
2.2. Bleomycin-induced pulmonary ﬁbrosis
In all experiments sex-matched UG-KO and WT littermates were
used. Four to six weeks old mice were anesthetized with ketamine
and varying doses (0.075 U, 0.0375 U or 0.0075 U/mouse) of bleomycin
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(Calbiochem, La Jolla, CA) in 50 ll sterile saline were intratracheally
administered. Control mice were treated with saline alone in the same
manner.
2.3. Histological analysis
The animals were killed 28 days after bleomycin or saline treatment,
the lungs were ﬁxed by intratracheal administration of 3.7% neutral
buﬀered formalin. After ﬁxation, the tissues were embedded in paraﬃn
and sectioned. Lung sections were stained with hematoxilin and eosin
or Masson’s trichrome stain (American Histolab, Inc., Gaithersburg,
MD). The stained tittue sections were examined using an Axiophot
Microscope (Carl Zeiss Microimaging, Inc.) and digital photomicro-
graphs were recorded.
2.4. Determination of hydroxylproline content in the lungs
The hydroxyproline content of mouse lung was determined colori-
metrically as described previously [10], with minor modiﬁcations.
Brieﬂy, the lungs were excised and weighted, trimmed free of surround-
ing conducting airways and hydrolyzed in 2 ml of 6 N HCl by autoclav-
ing at 120 C for 20 min. The resultant hydrolysate was neutralized with
2 ml of 6 N NaOH. Five microlitre of each sample was mixed with 5 ll
of citrate–acetate buﬀer (5% citric acid, 1.2% glacial acetic acid, 7.25%
sodium acetate, and 3.4% sodium hydroxide). One hundred microlitres
of chloramine-T solution (1.4% chloramines-T, 10% N-propanol, and
80% citrate–acetate buﬀer) was added, and the mixture was incubated
for 20 min at room temperature. Ehrlich’s solution was added and
the samples were incubated at 65 C for 18 min. The colored product
was measured at 560 nm and the amount of hydroxyproline was calcu-
lated from a standard curve constructed using hydroxyl-L-proline (Sig-
ma) at concentrations of 0.25–40 lg/ml. The data were expressed as
micrograms of hydroxyproline per gram of fresh lung tissue.
2.5. Analysis of bronchoalveolar lavage ﬂuid (BALF)
Seven days after bleomycin or saline treatment, bronchoalveolar la-
vage (BAL) was performed as previously described [8]. For diﬀerential
counts, cells were spun onto glass slides by cytocentrifugation and were
stained with HEMA3 (Fisher Scientiﬁc Co., Kalamazoo, MI). A total
of 500 cells per sample were analyzed.
2.6. RNA isolation and quantitative real-time PCR
Total RNA was isolated using TriZol (Invitrogen) following the
manufacturer’s protocol and further puriﬁed by QIAGEN RNeasy
Mini Kit and treated with DNAse (DNAse I, 30 U/lg total RNA)
(QIAGEN). Total RNA (2 lg) was reverse transcribed using Super-
Script III First-Strand Synthesis System (Invitrogen). Real time, quan-
titative RT-PCR analysis was performed by using the SYBR Green
PCR Master Mix and an ABI Prism 7000 Sequence Detection System
(Applied Biosystems). The cDNA equivalent of 10 ng total RNA was
used as the template. The PCR primers used are: IL-4: forward primer:
GGA GAT GGA TGT GCC AAA CG and reverse primer: CGA
GCT CAC TCT CTG TGG TGT T; IL-5: forward primer: TTG
ACA AGC AAT GAG ACG ATG AG and reverse primer: TCC
AAT GCA TAG CTG GTG ATT T; IL-13: forward primer: CGC
AAG GCC CCC ACT AC and reverse primer: AAA GTG GGC
TAC TTC GAT TTT GG; TGF-beta: forward primer: CGG AGA
GCC CTG GAT ACC A and reverse primer: TGC CGC ACA
CAG CAG TTC; pro-collagen Ia1: forward primer: GCT TCA CCT
ACA GCA CCC TTG T and reverse primer: GAT GAC TGT CTT
GCC CCA AGT T and b-actin: forward primer: ACG GCC AGG
TCA TCA CTA TTG and reverse primer: TGG AAA AGA GCC
TCA GGG C. The data, normalized to b-actin, were analyzed using
ABI Prism Software version 1.01 (Applied Biosystems) and presented
as fold increase compared with normal controls. Each experiment was
performed in triplicate for each group.
2.7. Western blot analysis
Total protein (15 lg) from each serum sample was resolved by SDS–
polyacrylamide gel electrophoresis, eletrotransferred to PVDF mem-
brane (Immobilon P, Millipore Corporation) and immunodetected.
The primary antibodies used are: anti-mouse IL-13 (1:1000; R&D)
and anti-bovine serum albumin (BSA) (1:2000; upstate). The second
antibodies used are: donkey anti-goat IgG and goat anti-rabbit IgG
(Santa Cruz Biotechnology).
2.8. Statistical analysis
Comparisons of data among each experimental group were evalu-
ated with Student’s t test of variance. Data are expressed as the means
(n=3) ± S.D. Data were considered signiﬁcant at P < 0.05.
3. Results and discussion
3.1. High mortality of UG-KO mice treated with bleomycin
To delineate whether the UG-KO mice are more susceptible
than their WT littermates to develop bleomycin-induced PF,
we ﬁrst studied the dose–response of bleomycin on UG-KO
mice and their wild type (WT) littermates by intratracheal
administration of varying doses of this drug. For each dose,
we treated 6–13 mice that are 4–6 weeks old. At this age, the
UG-KO mice do not develop any sign of pulmonary ﬁbrosis.
We used a dose of bleomycin (0.075 U/mouse) that is commonly
used to generate pulmonary ﬁbrosis inWTmice. We found that
28 days after intratracheal instillation of bleomycin the mortal-
ity inUG-KOmice reached 50%, comparedwith only 7% inWT
mice (Fig. 1). Thus, we lowered the bleomycin dose to 0.0375 U/
mouse and even then, 25% of the UG-KOmice died whereas all
of their WT littermates remained viable. We then used even a
smaller dose of bleomycin (0.0075 U/mouse) and at this dose,
none of these mice died throughout 28 days duration of the
experimental period (Fig. 1). Therefore, we used this lowest dose
for all of our experiments. Taken together, these results show
that lack of UG in these mice confers extreme sensitivity to ble-
omycin and causes high mortality.
3.2. UG-KO mice are highly susceptible to developing
bleomycin-induced PF
The results described above prompted us to determine
whether the lowest dose of bleomycin (0.0075 U/mouse) even
though it does cause death, induces PF in UG-KO mice.
Accordingly, this dose of bleomycin was intratracheally
administered in the UG-KO mice and their WT littermates.
The mice were killed 28 days after bleomycin treatment and
the lungs were analyzed histologically for the presence of PF.
The results show that compared with WT littermates
(Fig. 2A) UG-KO mice develop extensive PF at this lowest
dose of bleomycin (Fig. 2B). To conﬁrm the development of
PF, we stained the lung sections with Mason’s trichrome stain,
which readily identiﬁes the presence of collagen, characteristi-
cally found in PF, because of its blue color. The results show
that compared with the lungs of WT littermates (Fig. 2C) those
of the UG-KO mice manifest extensive deposition of collagen
(Fig. 2D) conﬁrming the presence of ﬁbrosis.
3.3. Low dose bleomycin stimulates the expression of additional
PF markers in the lungs of UG-KO mice
To determine the level of ﬁbrosis, we further analyzed addi-
tional molecular markers, which are associated with PF. First,
we measured the lung hydroxyproline content by colorimetric
method and analyzed the levels of collagen by quantitating
pro-collagen 1a1-mRNA expression by real time PCR using
total RNA from the lungs. The results show that compared
with bleomycin-treated WT mice, the levels of both hydroxy-
proline (Fig. 2E), and pro-collagen-1a1-mRNA (Fig. 2F)
expressions are signiﬁcantly elevated in the lungs of bleomy-
cin-treated UG-KO mice. Since transforming growth factor-b
(TGF-b) is a pro-ﬁbrotic cytokine that stimulates the migration
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as well as proliferation of ﬁbroblasts and are characteristically
associated with PF[11], we also analyzed the level of TGF b-
mRNA expression by quantitative real time PCR. Our results
show that TGF b-mRNA expression levels are signiﬁcantly ele-
vated (P < 0.005) in the lungs of UG-KO mice treated with ble-
omycin compared with those of their bleomycin-treated WT
littermates (Fig. 2G). These results conﬁrmed that all three crit-
ical molecular indicators of PF are markedly elevated in the
lungs of UG-KO mice treated with the lowest dose of bleomy-
cin that does not cause PF in WT littermates. These data
strongly indicate that lack of UG predisposes mice to develop-
ing PF even at an extremely low dose of bleomycin suggesting a
protective role of UG in the respiratory system.
3.4. Lowest dose of bleomycin induces markedly higher levels of
airway inﬂammation in UG-KO mice
It is well known that inﬂammation precedes ﬁbrosis. Thus,
we sought to determine whether the UG-KO mice are more
prone to developing exaggerated inﬂammatory response in
the lungs when treated with bleomycin. To explore this possibil-
ity, we histologically analyzed the lungs of UG-KO mice and
their WT littermates 28 days after bleomycin treatment. The re-
sults show that compared with the lungs of WT mice those of
the UG-KO mice contained markedly higher levels of inﬂam-
matory cells in the airways, and in the lung parenchyma (Sup-
plemental Figure 1). In related experiments, we further
analyzed the number and type of inﬂammatory cell populations
in the bronchoalveolar lavage ﬂuid (BALF) at seven days after
bleomycin administration, when the inﬂammatory response is
reported to be maximal. The results show that in the UG-KO
lungs the basal levels of all four categories of inﬂammatory
cells, eosinophils (Fig. 3A), neutrophils (Fig. 3B), lymphocytes
(Fig. 3C) and monocytes/macrophages (Fig. 3D), are higher
than in those of the WT littermates. Most interestingly, while
bleomycin treatment caused a moderate elevation in the num-
ber of these cells in WT lungs they were signiﬁcantly higher
(P < 0.05) in the bleomycin-treated UG-KO mouse lungs
(Fig. 3A–D). Taken together, these results suggest that the ex-
treme susceptibility of UG-KO mice to bleomycin-induced
inﬂammation may predispose them to develop PF.
3.5. Bleomycin induces higher levels of TH2 cytokine expression
in UG-KO lungs
Fibrosis is a particular concern in numerous persistent
inﬂammatory states driven by T helper type 2 (TH2) responses
[12]. It has been reported that the transcription of several
genes that are known to be involved in wound healing and
ﬁbrosis is upregulated by TH2 cytokines [5]. Cytokines have
also been reported to play critical roles in orchtrating aller-
gen-mediated airway inﬂammation [13]. Further, we previ-
ously reported that UG-KO mice manifest exaggerated
airway inﬂammation induced by a model allergen, ovalbumin
[8]. Thus, we analyzed the transcription levels of TH2 cyto-
kines, IL-4, IL-5 and IL-13 by real-time PCR. The results
show that the baseline levels of TH2 cytokines, especially IL-
4 and IL-13, are already higher in the lungs of UG-KO mice
(Fig. 4A and B). Interestingly, while there were no signiﬁcant
diﬀerence in the basal levels of IL5-mRNA expression in the
lungs of the WT and UG-KO mice bleomycin treatment ap-
pears to signiﬁcantly (P < 0.05) augment these basal levels
(Fig. 4C). Moreover, while low dose bleomycin treatment
did not markedly elevate the TH2 cytokine levels in WT lungs,
there were signiﬁcant (P < 0.05) augmentation of the already
elevated baseline levels of these cytokines in the bleomycin-
treated UG-KO mouse lungs (Fig. 4A–C). These results indi-
cate that bleomycin induces pulmonary inﬂammation by
stimulating the expression of pro-inﬂammatory TH2 cyto-
kines. Moreover, these results also indicate the likelihood that
Fig. 1. Uteroglobin-knockout mice are highly susceptible to developing bleomycin-induced pulmonary ﬁbrosis. Survival of UG-KO and WT mice
treated with varying doses of bleomycin. UG-KO or WT mice (n = 6–13) were treated with indicated doses of bleomycin and percent survival was
determined for each group throughout 28 days of experimental period. The data are representative of at least two separate experiments. Note the
strikingly lower percentage of survival of the UG-KO mice, which were treated with bleomycin dose 0.075 U/mouse and 0.0375 U/mouse,
respectively. Also note that 0.0075 U of bleomycin/mouse was tolerated by both UG-KO and WT littermates. Bleomycin-induced pulmonary ﬁbrosis
in WT and UG-KO mice.
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UG suppresses this stimulation in WT mouse lungs. Among
the TH2 cytokines, IL-13 has been reported to play the most
critical role in inducting ﬁbrosis. Therefore, we analyzed the
level of IL-13 protein in the serum of bleomycin treated and
untreated UG-KO as well as WT mice by Western blot anal-
ysis. The tissue expression of IL-13 in the lungs were also eval-
uated by immunohistochemical analysis. The results show that
compared with bleomycin-treated WT littermates the IL-13
protein levels in the serum of UG-KO mice are markedly
elevated (Fig. 4D). We also found that compared with the
lungs of WT littermates (Supplemental Figure 2A) a markedly
higher basal level of IL-13-speciﬁc staining was readily detect-
able in the airways of the UG-KO mice (Supplemental Figure
2B). More interestingly, while bleomycin treatment moder-
ately increased IL-13 staining in the airways of WT littermates
(Supplemental Figure 2C), it dramatically augmented that in
the airways of UG-KO mice (Supplemental Figure 2D). These
results strongly suggest that the bleomycin-induced exagger-
ated inﬂammatory response in the lungs of UG-KO mice is
mediated by the inﬁltration of the lungs with TH2 cells that se-
crete TH2 cytokines such as IL-13.
In this study, we sought to understand the molecular mech-
anism(s) of PF phenotype in UG-KO mice. We found that
UG, and indirectly the airway epithelial cells that secrete
UG, play critical roles in protecting the mammals from devel-
oping PF. It has been reported that the expression pattern of
epithelial cell-speciﬁc markers (e.g. surfactant protein C and
Clara cell speciﬁc protein, CC10) in the lungs of mice treated
with bleomycin is strain-speciﬁc [14–17]. It has also been dem-
onstrated that mice with the C57 genetic background are most
sensitive to bleomycin treatment [18]. Our UG-KO mice and
their WT littermates are of the C57 background. This is signif-
icant, as we have used the lowest dose of bleomycin that does
not induce PF in the WT mice of this sensitive C57 strain
although this low dose readily induces inﬂammation and
extensive PF in UG-KO littermates. These results strongly sug-
gest that UG confers resistance against the development of PF.
Howmight UG protect against PF? Our results show that the
anti-ﬁbrotic eﬀects of UG stems from its ability to prevent pul-
monary inﬁltration of TH2 cells that secrete pro-ﬁbrotic TH2
cytokines such as IL-4, IL-5 and IL-13. The anti-chemotactic ef-
fects of UGhave been reported previously [19] and this property
Fig. 2. Histological detection ﬁbrosis. Lung tissues from UG-KO mice and their WT littermates 28 days after bleomycin-treatment were stained with
hematoxylin–eosin (panels A and B) and Masson’s Trichrome (panels C and D) stains: WT (panels A and C) and UG-KO (panels B and D).
Compared with the lungs of WT littermates (panel C), Masson’s Trichrome staining show deposition of collagen (blue staining) in those of the UG-
KO mice (panel D). Magniﬁcation: 200· (panels A and B) and 630· (panels C and D). Hydroxyproline content (panel E) and pro-collagen 1a1
mRNA levels (panel F) in the lungs of bleomycin-treated mice and the proﬁbrotic cytokine TGF-b-mRNA expression in UG-KO mice and in their
WT littermates (panel G). Bars represent means ± S.E. with n = 3. *, P < 0.05; **, P < 0.01 compared with bleomycin-treated wild type mice group.
4518 Y.-C. Lee et al. / FEBS Letters 580 (2006) 4515–4520
Fig. 3. Extreme susceptibility of mice lacking uteroglobin to bleomycin-induced airway inﬂammation. Eosinophil (panel A), neutrophil (panel B),
lymphocyte (panel C) and monocyte/macrophage (panel D) cells in bronchoalveolar lavage ﬂuid (BALF) samples from WT and UG-KO mice at
seven days after administration of 0.0075 U/mouse of bleomycin (Blm) or PBS control (PBS). Bars represent means (n = 4–7) ± S.E. *, P < 0.01
compared with bleomycin-treated wild type mice group.
Fig. 4. Bleomycin induces high levels of TH2 cytokine expression in uteroglobin-knockout mouse lungs. The mRNA levels of TH2 cytokines were
determined by real-time PCR using total RNA from the lungs of WT and UG-KO mice at 28 days after treatment with bleomycin (Blm) or PBS
(control). IL-4 (panel A), IL-13 (panel B), IL-5 (panel C). Bars represent means (n = 3) ± S.E. *, P < 0.05. The Western blot analysis of IL-13 in the
serum of untreated and bleomycin-treated WT and UG-KO mice (panel D).
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of UG may be instrumental in preventing TH2 cell inﬁltration
of the lungs. It has been reported that TGF-b is one of the
cytokines that is consistently associated with PF[20,21]. Our
results show that bleomycin treatment markedly increases
the level of TGF-b-mRNA in the lungs of UG-KO mice. In
addition, the monocytes/macrophages, the cell type signiﬁ-
cantly increased in the lungs of bleomycin-treated UG-KO
mice, are known to express TGF-b [5]. Therefore, we sought
to determine whether UG downregulates the expression of
TGF-b-mRNA in a murine monocyte/macrophage cell line,
RAW 264.7. The results show that UG treatment indeed sup-
presses the expression of TGF-b-mRNA in these cells (Sup-
plemental Figure 3). The mechanism(s) by which UG
downregulates TGF-b-mRNA expression is not yet clear.
However, it is possible that UG exerts this eﬀect via its cell
surface receptor(s) [22–24].
Although the molecular mechanism(s) of PF is yet to be
clearly deﬁned, it appears that a breakdown of homeostatic
mechanisms to prevent pulmonary inﬂammation plays critical
pathogenic roles. Pulmonary ﬁbrosis aﬀects a large population
worldwide and currently, there is no eﬀective treatment for this
disease except for lung transplantation and supportive oxygen
therapy [5,6,10]. Current therapies are directed to suppress
lung inﬂammation that often precedes ﬁbrosis. However, these
treatments are eﬀective only in a small proportion of the af-
fected population. Further, while these treatments may inhibit
inﬂammation, they do not appear to prevent ﬁbrosis. Clearly,
understanding the homeostatic mechanism(s) in the mamma-
lian respiratory system that keeps inﬂammation at bay may
provide insight into the molecular mechanism(s) of this disease
and the development of novel therapeutic approaches. In this
regard, UG appears to maintain homeostasis in the mamma-
lian respiratory system to keep this vital organ free of inﬂam-
mation consequently, protects it from the development of
ﬁbrosis. Thus, the ﬁndings of this study, at least in part, pro-
vide a proof of principle that recombinant UG may have ther-
apeutic potential for PF.
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